Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 23, 2025 07:00 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

SAB to host webinar event to discuss Phase 1 clinical trial topline results
November 06, 2024 17:05 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
October 31, 2024 07:00 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference

SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
September 13, 2024 07:00 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

MIAMI, Sept. 13, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human...
September 09, 2024 07:00 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting

SAB BIO presents clinical trial progress update at EASD conference
September 04, 2024 07:05 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting

MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human...
August 08, 2024 17:51 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates

FDA provided clearance to SAB’s IND Appointed Lucy To as Chief Financial Officer Announced founding of a new Clinical Advisory Board MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) -- SAB BIO...
August 05, 2024 07:30 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes

MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing...
July 31, 2024 07:30 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO Appoints Lucy To as Chief Financial Officer

SAB BIO Appoints Lucy To as Chief Financial Officer
June 20, 2024 07:20 ET | Source: SAB Biotherapeutics, Inc.

SAb Biotherapeutics Rebrands as SAB BIO

New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1 diabetes MIAMI, June 20, 2024 (GLOBE...